Clinical trial
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
NCT02745769 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 21, 2016
- Completion date
- January 22, 2019
- Enrollment
- 23 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
advanced cancer, colorectal cancer, mantle cell lymphoma